

PROLIGHT RECEIVES SECOND NOTICE OF INTENTION TO GRANT FROM EUROPEAN PATENT OFFICE FOR PSYROS™ TECHNOLOGY

Prolight Diagnostics announces today that the company have received a Notice of Intention to Grant from the European Patent Office (EPO) for their second patent application related to the Psyros™ technology. This application (EP 4264266) is an extension to the core application (EP 3987287).

This application is an extension of the core patent to include methods to extend the lifetime of reactive oxygen species in order to make better defined spots in the sensor surface. This reduces the complexity of the optical readout system. A number of formalities will now take place before the process is complete and the patent is fully granted by the EPO.

“We are delighted that the EPO intends to grant our second patent application, following so closely after the intention to grant our first patent application. The examination process has highlighted the uniqueness of the Psyros™ technology and the lack of competition in this area,” said Steve Ross, CTO at Prolight Diagnostics.

“Strong patent protection makes Prolight even more attractive for strategic collaborations and in ongoing discussions with potential industrial partners,” said Ulf Bladin, CEO of Prolight Diagnostics.

Prolight currently have six families of patent applications relating to the Psyros™ technology. The first three are currently in the national / regional phases in a range of territories worldwide. Families four and five are in the PCT phase and will enter the national / regional phases later this year. The sixth is a priority application in the UK.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight receives second Notice of Intention to Grant from European Patent Office for Psyros™ technology